1 growth stock that could skyrocket over the next 10 years

This investor is excited about the transformational potential of one growth stock that he’s been eyeing up for his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Picking a growth stock that becomes a big winner over a decade or more can transform any investor’s returns. I know this from my own portfolio, where the flowers happily outshine the occasional giant weed.

Here, I’ll outline a high-risk, high-reward stock that’s recently piqued my interest.

An exciting gene-editing platform

The share is CRISPR Therapeutics (NASDAQ: CRSP). This biotech firm is focused on developing gene-editing therapies using CRISPR technology to treat genetic diseases, such as sickle cell disease and cancer.

Its breakthrough medicine, Casgevy, has now been approved in multiple countries. Developed in collaboration with Vertex Pharmaceuticals, this therapy treats sickle cell disease and transfusion-dependent beta thalassemia. Both are rare, debilitating blood disorders.

The treatment works by removing stem cells from a patient’s bone marrow, editing the faulty gene in a lab, then re-infusing the modified cells into the patient. It’s no exaggeration to call this transformative.

In August, the NHS announced it will begin rolling out Casgevy for beta thalassemia. There are about 460 patients in England potentially eligible for the treatment. It will cost about £1.65m ($2.09m) per patient.

Limited competition

CRISPR and Vertex see an addressable market of 35,000 patients in Europe and the US, with another 23,000 in Saudi Arabia and Bahrain.

Given the treatment costs $2m-$2.2m in Europe and the US, that’s a significant revenue opportunity. Vertex, with whom the firm will share product revenue, is predicting a “potential multi-billion opportunity”.

Better still, the therapy currently has no competition in Europe and the Middle East. In the US, it has a rival in the shape of Bluebird Bio, which has an approved sickle cell disease treatment. So that’s worth noting.

However, the market doesn’t seem to rate Bluebird’s prospects, given the stock is down 84% in one year and is priced at just $0.50. It has limited funds and its treatment is uncompetitively priced at $3.1m.

As of mid-July, Vertex had activated more than 35 treatment centres globally to collect patients’ cells. But since revenue is only recognized once patients receive their treatment, commercialisation is still in its early stages.

So while sales are expected to motor higher from 2025, potential delays could always arise.

Indistinguishable from magic

CRISPR stock skyrocketed to $199 in 2021, but has since fallen 74% to its current price of $50. This gives the firm a $4.3bn market cap.

For comparison, Vertex Pharmaceuticals is now a $123bn company after its share price surged around 4,350% over the past two decades. This shows what’s possible if a small biotech gets it right.

CRISPR ended Q2 with $2bn in cash and equivalents, so remains well-capitalised to advance its five other gene-editing medicines in clinical trials. Naturally though, there’s a risk some or all of these could fail.

Also, since these treatments are designed to be one-time cures, they’re unlikely to generate recurring sales like medications that require continuous use. Investors obviously favour recurring revenue.

Still, the high upfront price and likely expansion into other areas could drive significant financial success. Therefore, I think the stock could rocket in the years ahead and I’m considering buying it.

British science fiction writer Arthur C. Clarke once said: “Any sufficiently advanced technology is indistinguishable from magic.” This revolutionary gene-editing technology is akin to magic, in my opinion.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics and Vertex Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »